Not Signed In -
Rheumatoid Arthritis |
|
|
Clinical Trial: Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study
This study is no longer recruiting patients.
|
Purpose
The Rheumatoid Arthritis DMARD Intervention and Utilization Study (RADIUS 1) is designed to systematically collect and document use patterns, effectiveness, and safety of DMARD treatments currently used in the management of rheumatoid arthritis (RA). It is anticipated that study data may help improve the quality of information upon which clinical decisions are based.
| Condition | Intervention | Phase |
|---|---|---|
| Arthritis, Rheumatoid | Drug: DMARD | Phase IV |
MedlinePlus related topics: Rheumatoid Arthritis
Study Type: Observational
Study Design: Natural History, Longitudinal, Defined Population, Prospective Study
Official Title: Rheumatoid Arthritis DMARD Intervention and Utilization Study
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Fulfillment of the 1987 American Rheumatism Association criteria for RA
- Currently requiring a new DMARD (change or addition)
Exclusion Criteria:
- Currently enrolled in a clinical trial with treatments or patient visits imposed by a protocol
- Nursing or pregnant women
- Patients with active infection
Location Information
Study chairs or principal investigators
Willard Dere, M.D., Study Chair, Amgen
More Information
AmgenTrials clinical trials website
CenterWatch Clinical Trials Listing Service
Study ID Numbers: 20021634
Last Updated: July 26, 2005
Record first received: June 30, 2005
ClinicalTrials.gov Identifier: NCT00116714
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-08-02
Last Updated: July 26, 2005
Record first received: June 30, 2005
ClinicalTrials.gov Identifier: NCT00116714
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-08-02
email this page
print this page
bookmark this page
feedback on this page
